Status:
RECRUITING
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
Lead Sponsor:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions:
Cerebral Amyloid Angiopathy
CAA - Cerebral Amyloid Angiopathy
Eligibility:
All Genders
18+ years
Brief Summary
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, ...
Detailed Description
PRIORITY is a prospective, single-center observational study conducted at the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan. It will consecutively enroll patients over 18 years of age wit...
Eligibility Criteria
Inclusion
- patients of either sex over 18 years of age;
- patients with possible and probable symptomatic or asymptomatic CAA with or without histological demonstration (modified Boston criteria);
- patients who have had at least one brain MRI.
Exclusion
- patients who have contraindications to undergoing brain MRI (e.g., pacemaker, incompatible mechanical valves, claustrophobia);
- patients who have contraindications to or refuse to undergo lumbar puncture;
- patients who are unable to provide informed consent for the study due to aphasic or cognitive impairment;
- patients who are pregnant or breastfeeding.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06960538
Start Date
November 1 2021
End Date
September 1 2025
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy